Detection of target DNA with a novel Cas9/sgRNAs-associated reverse PCR (CARP) technique
This study develops a new method for detecting target DNA based on Cas9 nuclease, which was named as CARP, representing CRISPR- or Cas9/sgRNAs-associated reverse PCR. This technique detects target DNA in three steps: (1) cleaving the detected DNA sample with Cas9 in complex with a pair of sgRNAs specific to target DNA; (2) ligating the cleaved DNA with DNA ligase; (3) amplifying target DNA with PCR. In the ligation step, the Cas9-cut target DNA was ligated into intramolecular circular or intermolecular concatenated linear DNA. In the PCR step, the ligated DNA was amplified with a pair of reverse primers. The technique was verified by detecting HPV16 and HPV18 L1 genes in nine different human papillomavirus (HPV) subtypes. The technique also detected the L1 and E6–E7 genes of two high-risk HPVs, HPV16 and HPV18, in the genomic DNA of two HPV-positive cervical carcinoma cells (HeLa and SiHa), in which no L1 and E6–E7 genes were detected in the HPV-negative cervical carcinoma cell, C-33a. By performing these proof-of-concept experiments, this study provides a new CRISPR-based DNA detection and typing method. Especially, the CARP method developed by this study is ready for the clinical HPV detection, which was supported by the final clinical sample detection.
KeywordsCas9 Reverse primer PCR DNA Detection
This work was supported by the grants from the National Natural Science Foundation of China (grant 61571119).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures used in the present study were performed according to the Declaration of Helsinki. The Ethics Committee of Jinling Hospital (Nanjing, China) approved the present study. Written informed consent was obtained from all participants.
- 18.Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151–7.Google Scholar
- 20.Kilic G, Cardillo M, Ozdemirli M, Arun B. Human papillomavirus 18 oncoproteins E6 and E7 enhance irradiation- and chemotherapeutic agent-induced apoptosis in p53 and Rb mutated cervical cancer cell lines. Eur J Gynaecol Oncol. 1999;20:167–71.Google Scholar
- 25.Farhat S, Scott M, Ma Y, Moscicki A-B. Development of a novel liquid bead array human papillomavirus genotyping assay (PGMY-LX) and comparison with linear array for continuity in longitudinal cohort studies. J Clin Microbiol. 2015:JCM. 03100–14.Google Scholar
- 26.Tommasino M, editor. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol; 2014: Elsevier.Google Scholar
- 27.Han LL, Maimaitiming T, Husaiyin S, Wang L, Wusainahong K, Ma CH, et al. Comparative study of HPV16 integration in cervical lesions between ethnicities with high and low rates of infection with high-risk HPV and the correlation between integration rate and cervical neoplasia. Experimental and Therapeutic Medicine. 2015;10:2169–74.CrossRefGoogle Scholar
- 31.Tao P, Zheng W, Wang Y, Bian M-L. Sensitive HPV genotyping based on the flow-through hybridization and gene chip. BioMed Research International. 2012;2012.Google Scholar
- 33.Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol. 1996;34:2095–100.Google Scholar